Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.85 Billion KRW | -15.05% |
| 2022 | 3.4 Billion KRW | -20.08% |
| 2021 | 5.7 Billion KRW | -23.21% |
| 2020 | 10.17 Billion KRW | -15.46% |
| 2019 | 11.18 Billion KRW | 34.15% |
| 2018 | 7.45 Billion KRW | 39.36% |
| 2017 | 8.85 Billion KRW | -0.16% |
| 2016 | 8.56 Billion KRW | 22.71% |
| 2015 | 3.15 Billion KRW | 196.19% |
| 2014 | -6.09 Billion KRW | -217.48% |
| 2013 | 3.46 Billion KRW | -24.99% |
| 2012 | 5.26 Billion KRW | 48.2% |
| 2011 | 3.47 Billion KRW | -17.99% |
| 2010 | 3.66 Billion KRW | 47.0% |
| 2009 | 3.17 Billion KRW | 801.33% |
| 2008 | -37.66 Million KRW | -97.61% |
| 2007 | 14.72 Billion KRW | -20.18% |
| 2006 | 18.8 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 5.5 Billion KRW | -20.35% |
| 2024 Q1 | 6.06 Billion KRW | 1137.25% |
| 2023 Q1 | 13.81 Billion KRW | 1036.09% |
| 2023 Q2 | 660.69 Million KRW | -95.22% |
| 2023 Q4 | 1.2 Billion KRW | -89.21% |
| 2023 FY | - KRW | -15.05% |
| 2023 Q3 | 11.2 Billion KRW | 1595.85% |
| 2022 Q2 | 1.72 Billion KRW | -21.04% |
| 2022 FY | - KRW | -20.08% |
| 2022 Q4 | 1.21 Billion KRW | 106.23% |
| 2022 Q1 | 2.18 Billion KRW | 100.19% |
| 2022 Q3 | 589.7 Million KRW | -65.84% |
| 2021 FY | - KRW | -23.21% |
| 2021 Q1 | 2.09 Billion KRW | 100.02% |
| 2021 Q2 | 1.87 Billion KRW | -10.47% |
| 2021 Q3 | 2.08 Billion KRW | 11.31% |
| 2021 Q4 | 1.09 Billion KRW | -47.73% |
| 2020 Q1 | 4.24 Billion KRW | 34.55% |
| 2020 Q3 | 2.5 Billion KRW | 64.65% |
| 2020 Q4 | 1.04 Billion KRW | -58.19% |
| 2020 FY | - KRW | -15.46% |
| 2020 Q2 | 1.52 Billion KRW | -64.08% |
| 2019 Q1 | 2.85 Billion KRW | 26.41% |
| 2019 Q2 | 2.41 Billion KRW | -15.55% |
| 2019 FY | - KRW | 34.15% |
| 2019 Q4 | 3.15 Billion KRW | 20.96% |
| 2019 Q3 | 2.6 Billion KRW | 8.06% |
| 2018 Q1 | 2.98 Billion KRW | 0.0% |
| 2018 FY | - KRW | 39.36% |
| 2018 Q2 | 1.67 Billion KRW | -44.03% |
| 2018 Q4 | 2.25 Billion KRW | 73.48% |
| 2018 Q3 | 1.3 Billion KRW | -22.08% |
| 2017 Q3 | 1.51 Billion KRW | -30.34% |
| 2017 Q1 | 2.45 Billion KRW | 9.09% |
| 2017 FY | - KRW | -0.16% |
| 2017 Q2 | 2.16 Billion KRW | -11.72% |
| 2016 Q4 | 2.25 Billion KRW | 57.03% |
| 2016 Q1 | 3.52 Billion KRW | 264.23% |
| 2016 FY | - KRW | 22.71% |
| 2016 Q3 | 1.43 Billion KRW | 699.26% |
| 2016 Q2 | -239.4 Million KRW | -106.79% |
| 2015 FY | - KRW | 196.19% |
| 2015 Q4 | 967.56 Million KRW | 140.98% |
| 2015 Q3 | 401.51 Million KRW | 580.34% |
| 2015 Q2 | -83.59 Million KRW | 98.73% |
| 2015 Q1 | -6.56 Billion KRW | -641.66% |
| 2014 Q3 | 1.55 Billion KRW | 229.17% |
| 2014 FY | - KRW | -217.48% |
| 2014 Q4 | 1.21 Billion KRW | -21.83% |
| 2014 Q1 | 1.76 Billion KRW | 52.16% |
| 2014 Q2 | -1.2 Billion KRW | -167.9% |
| 2013 Q4 | 1.16 Billion KRW | 52.0% |
| 2013 Q1 | 4.1 Billion KRW | 490.86% |
| 2013 Q2 | 564.86 Million KRW | -86.25% |
| 2013 Q3 | 764.42 Million KRW | 35.33% |
| 2013 FY | - KRW | -24.99% |
| 2012 Q3 | 738.85 Million KRW | -12.89% |
| 2012 Q4 | 695.08 Million KRW | -5.92% |
| 2012 FY | - KRW | 48.2% |
| 2012 Q2 | 848.19 Million KRW | 0.0% |
| 2012 Q1 | - KRW | -100.0% |
| 2011 Q3 | 1.19 Billion KRW | 71.77% |
| 2011 Q2 | 697.47 Million KRW | -54.76% |
| 2011 FY | - KRW | -17.99% |
| 2011 Q1 | 1.54 Billion KRW | -41.13% |
| 2011 Q4 | 1.4 Billion KRW | 17.43% |
| 2010 Q4 | 2.61 Billion KRW | 451.96% |
| 2010 Q3 | -744.15 Million KRW | -163.24% |
| 2010 Q2 | 1.17 Billion KRW | -66.73% |
| 2010 Q1 | 3.53 Billion KRW | 25.66% |
| 2010 FY | - KRW | 47.0% |
| 2009 Q4 | 2.81 Billion KRW | 595.54% |
| 2009 Q3 | -568.02 Million KRW | 78.2% |
| 2009 Q1 | -2.6 Billion KRW | -40.17% |
| 2009 Q2 | -2.6 Billion KRW | 0.08% |
| 2009 FY | - KRW | 801.33% |
| 2008 Q1 | 2.1 Billion KRW | -62.63% |
| 2008 FY | - KRW | -97.61% |
| 2008 Q4 | -1.86 Billion KRW | -189.77% |
| 2008 Q3 | 2.07 Billion KRW | -24.58% |
| 2008 Q2 | 2.74 Billion KRW | 30.34% |
| 2007 FY | - KRW | -20.18% |
| 2007 Q2 | 3.29 Billion KRW | 0.0% |
| 2007 Q3 | 3.68 Billion KRW | 12.01% |
| 2007 Q4 | 5.64 Billion KRW | 53.11% |
| 2006 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 96.563% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 107.587% |
| HANDOK Inc. | 35.06 Billion KRW | 86.145% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 568.691% |
| Yuhan Corporation | 127.43 Billion KRW | 96.188% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 87.052% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 122.402% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 98.497% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 2.645% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 67.864% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -42.016% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -7.333% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 86.309% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 126.301% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 25.883% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 109.856% |
| JW Holdings Corporation | 187.88 Billion KRW | 97.414% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 109.484% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 98.287% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 94.555% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 113.107% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 63.221% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 58.925% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 73.957% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 91.162% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 97.054% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 94.555% |
| Yuhan Corporation | 127.43 Billion KRW | 96.188% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 85.487% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 36.491% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 93.693% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 94.555% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 86.738% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 93.136% |
| CKD Bio Corp. | -1.63 Billion KRW | 397.976% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 90.243% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 85.079% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 86.802% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 113.107% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 92.2% |
| Boryung Corporation | 114.28 Billion KRW | 95.749% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 115.893% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 67.864% |
| JW Lifescience Corporation | 50.82 Billion KRW | 90.442% |